NSABP FC-6: Phase II Study to Determine Surgical Conversion Rate in Patients (pts) Receiving Neoadjuvant (NA) mFOLFOX7 Plus Dose-escalating Cetuximab (C) for Unresectable K-RAS Wild-type (WT) Colorectal Cancer with Metastases (mCRC) Confined to the Liver
ANNALS OF SURGICAL ONCOLOGY（2014）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要